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A B S T R A C T
In recent years, lipodystrophy and its related complications have become one of the major problems confronting HIV-
-infected patients on antiretroviral therapy. More than ten years after having been described for the first time, compre-
hensive knowledge of its underlying molecular basis, the natural history of body fat changes and metabolic abnormali-
ties, and even a working definition of lipodystrophy are all still lacking. No standardized objective assessment of body fat
has been incorporated into clinical practice for patient monitoring. Although a huge amount of data has been generated,
no clinically proven treatment for any feature of lipodystrophy is currently available. The only intervention that has been
shown to reverse lipoatrophy had been the discontinuation of thymidine analogues, although even then the results ob-
tained are at most partial or modest. Recently published studies using uridine (NucleomaxX) and pravastatin resulted
in a significant increase of subcutaneous fat. The potential for reversing lipodystrophy once it has developed is limited,
but promising results in preventing it are obtained with thymidine analogue-sparing initial antiretroviral regimens.
These results raise the question of whether we may be facing a definitive solution to the lipodystrophy syndrome.
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Introduction
Lipodystrophy in HIV-1-infected patients represents
an adverse effect of antiretroviral therapy not limited to
a specific drug or class of drugs.
HIV-associated lipodystrophy may affect up to half or
more of HIV-infected patients receiving antiretroviral
therapy1,2. The word »lipodystrophy« has an imprecise
meaning, and as understanding of the problem has be-
come more sophisticated, the definition of lipodystrophy
has been further obscured. »Lipodystrophy« is generally
used to refer to a syndrome of peripheral fat wasting
(lipoatrophy) and central fat accumulation (lipohyper-
trophy). However, at present, it is not completely known
whether lipodystrophy is one unique syndrome or sev-
eral different overlapping syndromes.
Several metabolic abnormalities, such as dyslipidemia
and insulin resistance, have also been reported in pa-
tients receiving antiretroviral therapy. These metabolic
changes may increase the risk for cardiovascular di-
sease3. Other events such as hyperlactatemia, low bone
mineral density, avascular necrosis, hypogonadism and
hypertension have been described, though their relation-
ship with lipodystrophy syndrome has not been clearly
established.
Im addition to these medical issues, body fat changes
are disfiguring, can be stigmatizing, and may lead to so-
cial isolation, and thus a poorer adherence to and even-
tual failure of antiretroviral therapy. Knowledge of some
aspects of this problem has increased in recent years, but
many important questions remain unanswered.
Definition of Lipodystrophy
Lipodystrophy emerged as an unexpected problem in
the field of HIV disease. To date, the most common way
to diagnose lipodystrophy is by subjective description of
body fat changes. Two multicenter studies have recently
undertaken the task of establishing objective criteria for
defining lipodystrophy. The Lipodystrophy Case Defini-
tion Study compared patients with and without evident
clinical signs of lipodystrophy, agreed upon by the patient
and the doctor. Laboratory, anthropometrical, and radiol-
ogy (including CT scan and dual X-absorptiometry or
DEXA) data were compared between the two groups of
patients, with a goal of creating a quantitative scoring
system by which to define lipodystrophy4. The generated
definition of lipodystrophy had an 80% sensitivity and
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specificity, but was shown to be too complex to be used as
a regular part of clinical practice. The Fat Redistribution
and Metabolic Changes in HIV Infection (FRAM) study
compared laboratory, anthropometric, and radiologic
data of HIV-infected and non-HIV-infected subjects. The
FRAM study showed that generalized lipoatrophy, not
lipohypertrophy, was the only distinctive body fat change
associated with HIV infection5. The results of the FRAM
study do not explain why the prevalence of intra-abdomi-
nal obesity is so high is HIV-infected individuals. How-
ever, other studies also agree that lipoatrophy is the hall-
mark of body fat changes in HIV-infected people6,7.
Measurement
Objective criteria for diagnosing lipodystrophy are
still not established. The word lipodystrophy has a vague
meaning, becoming even much more vague as the prob-
lem has become more complex over time. Patient descrip-
tion of fat redistribution, confirmed by physician exami-
nation, remains the preferred method for describing the
problem individually. But objective criteria for diagnos-
ing lipodystrophy are still not established. The lack of
standardized values of fat gain in the general population
and the heterogeneity of the clinical manifestation of
lipodystrophy complicate matters even further. There is
no gold-standard method for measuring body fat. How-
ever, several techniques have been used: anthropometry,
bioimpedance analysis, DEXA, computed tomography,
magnetic resonance imaging and ultrasonography. Each
of these techniques has limitations. Anthropometry and
bioimpedance analysis cannot measure regional body fat.
Computed tomography and magnetic resonance imaging
are expensive, and use may be restricted8,9. Ultrasono-
graphy is promising because of its simplicity, safety, avail-
ability and low cost, although it is more operator-depend-
ent than other techniques. DEXA has gained popularity
and is probably most extensively used at present10,11. Few
data are available on the comparison of these objective
techniques for measuring regional body fat. It seems that
the measurement of absolute values of regional fat is
highly correlated12.
Another important issue is whether it is necessary to
incorporate objective measurements of regional body fat
into clinical practice, for anything other than investiga-
tional purposes. Despite enthusiasm for determining the
best method for quantifying regional fat, the clinical util-
ity of such measurements has not been established. Avail-
ability and cost pose further barriers to clinical use of ob-
jective measurement of regional body fat.. However, ob-
jective evolution of even minimal changes needs to be
measured, in order to prevent or diminish further pro-
gression as well as to accurately evaluate possible inter-
ventions.
Pathological Mechanisms
The etiology of HIV-associated lipodystrophy seems to
be multifactorial. Several studies have demonstrated
that various risk factors may play an important role in
the pathogenesis of lipodystrophy. Risk factors can be di-
vided into several groups: host factors (gender, age, race,
genetic factors, initial total body fat content), environ-
mental factors (nutrition, exercise level) antiretroviral
therapy (duration of and drugs used), immunological re-
sponse, HCV coinfection, as well as HIV-1 infection itself.
Underlying environmental and host factors are difficult
or impossible to modify, and clinical trials have clearly
demonstrated that the contribution of choice and duration
of antiviral therapy are key risk factors in the develop-
ment of body fat changes. The choice of initial anti-
retroviral therapy is very important in preventing devel-
opment of lipodystrophy. For example, we now know that
thymidine analogue-sparing first line regiments cause
less lipoatrophy than thymidine analogue-containing re-
gimens13,14.
Managing HIV Lipodystrophy
So far, there is no adequate treatment to reverse
lipodystrophy. Diet is of little use by itself, unless dietary
abnormalities are present15. Exercise may lead to a par-
tial beneficial decrease of central fat accumulation and
triglycerides, but at the expense of increased peripheral
fat wasting16,17.
The impact of discontinuing antiretroviral drugs sup-
posedly involved in the pathogenesis of lipodystrophy
syndrome has been assessed in different studies. The
earliest studies discontinued protease inhibitors18,19. In
general, switching protease inhibitors may improve met-
abolic abnormalities, but the impact on body fat is very
scarce or null Switching thymidine analogues (most data
coming from stavudine and/or zidovudine discontinua-
tion) has been the only intervention seen to improve
lipoatrophy20-23.
The effect of discontinuing all antiretroviral therapy
on the evolution of lipid abnormalities and body fat is
poorly understood. Some preliminary data obtained from
a group of well-controlled patients with primary HIV in-
fection show a gain of total and regional fat during con-
secutive cycles of structured treatment interruptions24,25.
This issue is being addressed in ongoing large-scale stud-
ies.
Treatment with thiazolidinediones and leptin has
shown good results in a population of non-HIV-infected
patients with genetic and autoimmune lipodistrophy26,27.
Moreover, two small-uncontrolled studies suggested that
rosiglitazone might contribute to fat gain regardless of
ongoing antiretroviral therapy28,29. Randomized, place-
bo-controlled studies, though, have shown that rosigli-
tazone does not improve fat mass in HIV-lipoatrophy,
and can possibly worsen dyslipidemiae despite an im-
provement of insulin sensitivity29,30.
Data from randomised studies comparing effects of
metformin, gemfibrozil and placebo in patients receiving
HAART have found less fat loss with gemfibrozil than
with placebo, no effect of metformin, while all patients
lost fat over time31.
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One recently published study reported a significant
increase of subcutaneous fat with twelve weeks of treat-
ment with pravastatin32. Pravastatin use has not been
previously reported to have any effect on subcutaneous
fat, but these results suggest there may be a place for
paravastatin in the treatment of HIV-related lipoatrophy.
Uridine use may provide an additional treatment op-
tion. In a study designed to investigate the effect of
uridine (36g NucleomaxX three times a day for 10 days/
month over 3 months) an increase in the amount of sub-
cutaneous fat was observed33.
These findings need to be further investigated in
large randomized prospective trials.
Since current treatments for lipoatrophy take time
and may provide only modest improvement, there is a
growing demand for interventions with immediate re-
sults. Advances in the field of plastic and reparatory sur-
gery have proven to be popular treatment options. Lipo-
suction performed in some patients with severe buffalo
hump or increased subcutaneous fat deposits showed
showed good short-term results, but some patients re-ac-
cumulated fat over the following months34,35. Unfortu-
nately, there is still no treatment available for patients
with visceral fat accumulation.
Implant surgery for facial lipoatrophy can be per-
formed using permanent or biodegradable implants such
as polylactic or hyaluronic acid, or autologous fat from the
dorsocervical or subcutaneous abdominal area36,37. Treat-
ment of facial lipoatrophy by injecting autologous adipose
tissue (Coleman’s lipostructure) seems to be a satisfactory
and cost-effective option to treat facial lipoatrophy if there
is an existing source of fat graft38. Prospective studies are
ongoing to assess the durability and potential differences
among different surgical interventions39.
Conclusions
HAART has dramatically altered the natural history
of HIV disease 40. HIV-related lipodystrophy has emerged
as one of most prevalent and worrisome problems for
HIV-infected patients now when significant improve-
ment in long-term prognosis of HIV-related immune sup-
pression is provided. Great improvements in the under-
standing of lipodystrophy have been achieved, though
there is still much to be learned. A definition of lipo-
dystrophy has yet to be established. A clinically proven
definitive treatment for any feature of lipodystrophy
does not exist.
The only intervention that has been shown to revert
lipoatrophy had been the discontinuation of thymidine
analogues, although results obtained are at best partial
and slow. Structured therapy interruption has become an
increasingly popular strategy aimed among other things,
preventing antiretroviral drug toxicity, but few objective
data exist on the impact on the body composition of
HIV-infected patients.
Studies using pravastatin and uridine have led to en-
couraging reversal of subcutaneous fat loss, and further
studies are ongoing. Plastic surgery may give satisfac-
tory, though not always permanent, aesthetic results in
the absence of other definitive options.
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LIPODISTROFIJA POVEZANA S HIV-INFEKCIJOM
S A @ E T A K
Lipodistrofija i komplikacije povezane s njom postale su proteklih godina jedan od glavnih problema koje susre}u
bolesnici zara`eni HIV-om koji primaju antiretrovirusne lijekove. Deset godina nakon prvih opisa znanje o moleku-
larnoj podlozi, prirodnom tijeku i metaboli~kim abnormalnostima pa ~ak i radna definicija lipodistrofije jo{ nedostaju.
Nije uveden niti standardiziran postupak procjene tjelesnog masnog tkiva u klini~ku praksu. Usprkos niza istra`ivanja
zasad ne postoji klini~ki dokazano lije~enje bilo kojeg oblika lipodistrofije. Jedina intervencija koja je pokazala regresiju
lipoatrofije je prekid lije~enja analozima timidiana, iako je i u toj situaciji u~inak bio djelomi~an ili skroman. Nedavno
objavljena istra`ivanja primjene uridina (NucleomaxX) i pravastatina pokazala su zna~ajno pove}anje potko`nog mas-
nog tkiva. Mogu}nosti popravljanja lipodistrofije kada je ona ve} razvijena su ograni~ene ali ohrabruju rezultati sprje-
~avanja nastanka lipodistrofije kada se u po~etnom antiretrovirusnom lije~enju primjenjuju lijekovi koji nisu analozi
timidina. Ovi rezultati postavljaju pitanje da li smo suo~eni s kona~nim rje{enjem sindroma lipodistrofije.
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